{"id":"early-receiving-g-csf-group","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Bone pain"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Fatigue"},{"rate":"5–15%","effect":"Injection site reactions"},{"rate":"5%","effect":"Splenomegaly"},{"rate":"5–10%","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and mobilization. Early administration of G-CSF helps prevent or mitigate chemotherapy-induced neutropenia by boosting neutrophil production before or immediately after cytotoxic treatment, reducing infection risk and allowing patients to tolerate higher chemotherapy doses.","oneSentence":"G-CSF (granulocyte colony-stimulating factor) stimulates the bone marrow to produce and release neutrophils into the bloodstream to increase white blood cell counts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:02.306Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of chemotherapy-induced neutropenia in cancer patients receiving myelosuppressive chemotherapy"},{"name":"Mobilization of peripheral blood progenitor cells for stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06361329","phase":"PHASE3","title":"Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-04-03","conditions":"ETP-ALL","enrollment":81},{"nctId":"NCT06665737","phase":"PHASE4","title":"Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2025-02-01","conditions":"Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN)","enrollment":126},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT00274924","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-09-26","conditions":"Lymphoma","enrollment":100},{"nctId":"NCT00061893","phase":"PHASE2","title":"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-04","conditions":"Sarcoma","enrollment":38},{"nctId":"NCT02072811","phase":"PHASE3","title":"Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"dr hab. n. med. Agnieszka Wierzbowska","startDate":"2014-02","conditions":"Acute Myeloid Leukemia","enrollment":400},{"nctId":"NCT00006363","phase":"PHASE3","title":"Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-11","conditions":"Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6)","enrollment":720}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Early receiving G-CSF group","genericName":"Early receiving G-CSF group","companyName":"Department of Medical Services Ministry of Public Health of Thailand","companyId":"department-of-medical-services-ministry-of-public-health-of-thailand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Early receiving G-CSF group is associated with the treatment of Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) in adult patients. G-CSF is used as a component in the treatment regimen, specifically in the context of a double induction therapy for AML.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}